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The objective of this study was to examine the ability of a novel microencapsulated probiotic yogurt formulation to suppress the
intestinal inﬂammation. We assessed its anticancer activity by screening interleukin-1, 6, and 12 (IL-1, 6, 12), secretory levels of
t u m o rn e c r o s i sf a c t o r - a l p h a( T N F - α), interferon-gamma (IFN-γ), prostaglandin E2 (PGE2), and thromboxane B2 in the digesta
obtained from the duodenum, jejunum, proximal, and distal segments of the ileum of C57BL/6J-Apc
Min/J mice. Formulation-
receiving animals showed consistently lower proinﬂammatory cytokines’ levels when compared to control group animals receiving
empty alginate-poly-L-lysine-alginate (APA) microcapsules suspended in saline. The concentrations of IL-12 found in serum in
control and treatment group animals were signiﬁcant: 46.58 ± 16.96pg/mL and 158.58 ± 28.56pg/mL for control and treatment
animals, respectively. We determined a signiﬁcant change in plasma C-reactive protein: 81.04 ±23.73ng/mL in control group and
64.21 ± 16.64ng/mL in treatment group. Western blots showed a 71% downregulation of cyclooxygenase-2 (COX-2) protein in
treatment group animals compared to control. These results point to the possibility of using this yogurt formulation in anticancer
therapies, in addition to chronic gut diseases such as Crohn’s disease, irritable bowel syndrome (IBS), and inﬂammatory bowel
disease (IBD) thanks to its inﬂammation lowering properties.
1.Introduction
The burden of colon cancer in Western countries is over-
whelming,amountingto50000deathsperyearinUSAalone
[1]. Much eﬀort is being devoted to the development of
eﬀective therapies for this disease as well as to its prevention.
Inﬂammation plays a major role in pathogenesis of col-
orectal cancer, and its evaluation is a powerful tool in screen-
ing and understanding the key components that lead to
this complex disorder. Normally, the intestinal microﬂora is
eﬀectivelyconﬁnedtothelumenbytheepithelium.However,
intestinal epithelial barrier defects, for instance, disrupted
epithelial tight junctions (leaky gut) may contribute to the
chronic inﬂammation as bacteria that translocate through
the epithelium may expose submucosal immune cells to
inappropriate antigenic stimulation and incite an inﬂamma-
tory response towards the commensal microﬂora [2].
The recognition of the compelling association between
intestinal inﬂammation leading to such disorders as Crohn’s
disease (CD), ulcerative colitis (UC), and colon cancer has
led to an abundance of studies investigating the therapeutic
potential of altering luminal bacteria using probiotics.
Probiotics are deﬁned as living organisms in food and
dietary supplements which, upon ingestion, improve the
health of the host beyond their inherent basic nutrition [3].
Probiotic bacteria have beneﬁcial eﬀects on the intestinal
epithelia both directly and indirectly, including enhanced
barrier function, modulation of the mucosal immune sys-
tem, production of antimicrobials, and alteration of the
intestinal microﬂora [4].2 International Journal of Inﬂammation
The story of probiotics reaches far into the 1850s
when Louis Pasteur identiﬁed the ﬁrst probiotic bacteria,
Lactobacillus, and in 1900 Dr. Henry Tissier was the ﬁrst
person to attempt using bacteria to treat intestinal diseases.
By the 1920s, Lactobacillus acidophilus was successfully used
by the United States to treat diarrhea and constipation.
Today, performance and eﬃcacy testing of probiotic bacteria
in gastrointestinal disorders, both in animal studies and
clinical trials, continues to be of great interest [5, 6].
Furthermore, speciﬁcstrains of bacteriahave been impli-
cated in the pathogenesis of colon cancer [7, 8], in particular,
Lactobacillus acidophilus and Biﬁdobacterium longum have
been shown to reduce incidence of colonic tumors and
aberrant crypt foci, respectively, in animal models [9, 10].
Although many studies suggest that probiotics are capable
of preventing relapse of chronic intestinal inﬂammation and
have beneﬁcial contributions in disorders such as diarrhea,
gastroenteritis, irritable bowel syndrome, and inﬂammatory
bowel disease [11, 12], their therapeutic potential has been
hampered by inherent limitations in their use, for example,
poor survival during gastric transit, concerns regarding the
production, cost, storage, and safety. Microencapsulation is
a technique which oﬀers protection to live bacteria from
the harsh gastrointestinal environment during transit by
use of specialized ultrathin semipermeable polymer mem-
branes [13]. It also limits stimulation of the host immune
response as well as minimizes risks of systemic infections,
the replacement of the normal intestinal ﬂora and gene
transfer [14].
There are many tumor markers which can be measured
whose measurement or identiﬁcation is useful in patient
diagnosis or clinical management in cancer. However, as no
single marker has been established yet as a practical cancer
screening tool either in a general healthy population or in
most high risk populations, a set of tests needs to be per-
formedin order todraw conclusions. Cyclooxygenase(COX)
isanenzymewhichcatalyzestheﬁrststepintheformationof
prostaglandins (PGs), the conversion of arachidonic acid to
PGH2, followed by the metabolism of PGH2 to biologically
active end-products, PGD2,P G E 2,P G F α2,P G I 2, or throm-
boxane A2 (TxA2) via speciﬁc synthases [15]. Two cyclooxy-
genase isoforms, COX-1 and COX-2, have been identiﬁed.
COX-2 is critical for the development of colorectal neoplasia
[16]. COX-2 inhibitors can reduce intestinal inﬂammation
leading to tumorigenesis [17] and are therefore used to
treat familial adenomatous polyposis (FAP) patients [18]
and patients with colorectal cancer [19]. Accumulating
evidence has shown that prostaglandin E2 (PGE2), the main
product of cyclooxygenase-2 (COX-2) activity, can promote
a number of molecular mechanisms involved in colorectal
carcinogenesis [20] in particular tumor cell proliferation
and angiogenesis [21–24]. C-reactive protein (CRP) is an
acute-phase systemic protein produced primarily in the liver
in response to stimulation by interleukin-6 (IL-6) [25]. In
additiontostudieswhichshowconsistencyindemonstrating
an increased risk of mortality due to inﬂammation and
subsequent cancer development, CRP and IL-6 have been
shown to be associated with total and noncardiovascular
mortality [26–28].
Tumor necrosis factor-α (TNF-α) and interleukin 1-β
(IL1-β) seem to play an important role in ulcerative colitis
(UC) in relevant experimental models [29] and are linked
to colorectal cancers via inducing the expression of vascular
endothelial growth factor (VEGF) [30, 31] or causing a
signiﬁcant increase in the release of soluble B7-H3 in colon
cancer cell lines [32].
In this study, we investigated the potential of microen-
capsulated probiotic bacterial cells contained within our
yogurtformulationinreducingintestinalinﬂammationinan
animalmodelforcolorectalcancer,C57BL/6J-ApcMin/Jmice.
We provide evidence that the daily gavage of the probiotic
formulation to mice reduces expression of COX-2 as well
as lowers plasma C-reactive protein (CRP) levels. We have
quantiﬁedthelevelsofsecretorycytokinesIL-1β,IL-6,IL-12,
PGE2,T N F - α,I F N - γ, and Thromboxane B2 in ileal contents.
2.MaterialsandMethods
2.1. Chemicals. Sodium alginate (low viscosity), poly-L-
lysine hydrobromide (MW = 27,400), and calcium chlo-
ride (A.C.S. reagent) were purchased from Sigma-Aldrich,
Canada. Difco Lactobacilli MRS AGAR and Difco Lacto-
bacilliMRSBROTHwerepurchasedfromBecton,Dickinson
and Company Sparks, USA. Liberty plain yogurt 2% M.
F. containing bacterial cultures Streptococcus Thermophilus,
Lactobacillus Acidophilus, Biﬁdobacterium biﬁdum, and Lac-
tobacillus bulgaricus was procured from a local grocery store.
It contained Calories: 110kcal, fat: 3.5g, carbs: 9g, protein:
9g ,v i t a m i nA6 % ,c a l c i u m3 0 %v i t a m i nC4 % ,a n di r o n0 %
per 175g serving.
2.2. Bacteria and Culture Conditions. Bacterial strain of Lac-
tobacillus acidophilus no. 314 ((Moro) Hansen and Mocquot
deposited as Bacillus acidophilus Moro, Designation 43)
used in this study was obtained from ATCC (Manassas,
VA) and was cultivated and serially propagated in the
MRS medium before experimental use. Incubations were
performed at 37
◦C in a Professional Sanyo MCO-18M
Multi-Gas Incubator under anaerobic conditions (1-2%
CO2, Atmosphere Generation System AnaeroGen; Oxoid
Ltd., Hampshire, England). Bacteria were harvested after 20
hours of the 3rd passage for encapsulation.
2.3. Microencapsulation Method. The bacterial strains
were microencapsulated into alginate-poly-L-lysine-alginate
(APA) membranes. All membrane components were ﬁlter
sterilized through a 0.22μm Sterivex-GS ﬁlter (Millipore,
Bedford, MA, USA) prior to use. Grown cultures were
centrifuged at 3000×gf o r1 5m i n u t e sa t2 5
◦C, and the
supernatant broth was decanted. The pellet of wet cells
was weighed and suspended in 0.85% saline, pooled, and
slowly added to a gently stirred sterile 3.3% sodium alginate
solution (ﬁnal concentration adjusted to 1.65% with 0.85%
saline). The entire procedure was performed under sterile
conditions in Microzone Biological Containment Hood
(Microzone Corporation, ON, Canada) and all solutions
were autoclaved with the exception of poly-L-lysine which
was0.22μmsterileﬁlteredpriortousage.APAmicrocapsulesInternational Journal of Inﬂammation 3
were prepared aseptically using an Inotech Encapsulator
IER-20 (Inotech Biosystems Intl. Inc., Switzerland). Freshly
prepared microcapsules were washed twice with 0.85%
s a l i n ea n ds t o r e da t4 ◦C. Parameters for microencapsulation
were as follows: gelation time in CaCl2—30 minutes, coating
time—10 minutes, nozzle diameter—300μm, vibrational
frequency—918Hz, voltage >1.00kV, and current 2amp.
2.4. Preparation of Probiotic Formulation. APA microcap-
sules loaded with L. acidophilus bacterial cells were carefully
mixed with Libert´ e plain yogurt 2% M.F. and suspended
in sterile 0.85% saline to 80% (vol/vol) ﬁnal concentration.
The bacterial cell count was kept constant at 1010 cfu/mL
throughout the experiment. Empty APA microcapsules were
suspended in 0.85% saline using the same formulation and
stored at 4◦C until further use.
2.5. Animals. Male heterozygous C57BL/6J-ApcMin/J [33]
mice, 5 or 6 weeks old, were obtained from The Jackson
Laboratory (Bar Harbor, ME). Multiple intestinal neoplasia
( M i n )m i c ea r eh e t e r o z y g o u sf o rApc (Min/+), a germ-
line truncating mutation at codon 850 of the Apc gene,
and spontaneously develop pretumoric numerous intestinal
neoplasms. They are a popular animal model for studies on
human colorectal cancer [33]. The animals were housed in
the McIntyre Medical Sciences Building Animal Care Facility
in a room with a 12-hour light-dark cycle and controlled
humidity and temperature. The mice were maintained in
a barrier facility. They were allowed sterile water and the
laboratory rodent diet 5001 from Purina Land O’Lakes ad
libitum. Overall health of the animals was monitored daily.
The animal use protocol was approved by the Animal Care
Committee of McGill University, and animals were cared
for in accord with the Canadian Council on Animal Care
(CCAC) guidelines.
2.6. Experimental Design. Upon arrival, animals were kept
in a sterile environment in individual ventilated cages (IVCs)
which ﬁlter the air with HEPA ﬁlters. The cages, food,
water bottles, and so forth were autoclaved. Animals were
randomly placed in the cages and allowed one week of
acclimatization. The animals were ranked and assigned to
groups according to a randomized block design. The mice
were separated into two experimental groups: control (n =
24) animals were gavaged 0.3 mL of 0.85% saline solution
and treatment animals (n = 24) were gavaged 0.3mL of
APA microencapsulated L. acidophilus bacterial cells blended
in 2% M.F. yogurt for the total of 0.66 × 1010 cfu/mL of
encapsulated bacterial cells per mouse per day. The caloric
content of each gavage (0.125kcal) was considered to be
an insigniﬁcant factor in potential animal weight gain and
therefore not taken into account. Animals were weighed
individually every week, and their food consumption was
weighed per cage of 4 animals. Blood collection from the
saphenous vein was performed every 4 weeks. Blood was
separated using 5000×ga t4 ◦Cf o r1 0m i n u t e s .
2.7. Luminal Digesta. At the time of sacriﬁce, the small
intestine of each animal was measured and cut into 4 equal
segments, eachapproximately representing a distinctive part,
namely, duodenum, jejunum, and proximal and distal ileum.
Each segment was ﬂushed with cold D-PBS buﬀer (Gibco),
its contents were collected and ﬂash frozen at −85
◦C.
Before analyses, the digesta samples were thawed and treated
with 1.0% BSA-50mM Tris buﬀer (pH 7.5) for 60min at
room temperature to separate the food matrix from cellular
material. The samples were then centrifuged at 50,000×g
for 15min. The supernatants were stored at −85
◦Ca n du s e d
later for measurements.
3.AnalyticalMethods
3.1. Quantiﬁcation of IL-1β, IL-6, IL-12, PGE2, Thromboxane
B2, TNF-α,I F N - γ, and CRP Expressions Using ELISA.
IL-1β, IL-6, and IL-12 were quantiﬁed using kits from
Biosource, Invitrogen, USA according to manufacturer’s
recommendations. PGE2 was measured using a competitive
enzyme immunoassay (Cayman Chemical, Ann Arbor, MI)
as described previously in [34]. Brieﬂy, 96-well plates were
p r e c o a t e dw i t ht h ec a p t u r eA b( g o a ta n t i m o u s eA b ) .1 0 0μL
enzymeimmunoassay(EIA)buﬀerwasloadedtononspeciﬁc
binding (NSB) wells. 50μLE I Ab u ﬀer was loaded to
maximum binding (B0) wells. 50μLP G E 2 standards were
loaded into appropriate wells. 50μL of samples or standards
were incubated with 50μLo fP G E 2 tracer and 50μLo f
PGE2 mAb overnight at 4◦C. After three washes in wash
buﬀer, 200μL of Ellman’s reagent was added to the plate
and allowed to incubate for 1h for the color to develop.
The optical Density (OD) was determined using the Perkin
Elmer Victor microtiter plate reader at 405nm, and PGE2
production was expressed as picograms per milligram.
Thromboxane B2 (Express EIA kit-monoclonal, Cat.No.
10004023,CaymanChemical,AnnArbor,MI)wasmeasured
according to manufacturer’s instructions. TNF-α was mea-
sured using a competitive enzyme immunoassay (Cat.No.
KMC3012, Immunoassay Kit, Biosource Int., Inc, USA)
accordingtomanufacturer’sinstructions.Biotingammarab-
bit antimouse interferon-γ was purchased from Cedarlane,
(Hornby, ON, Canada) and reconstituted from sterile form
to 50μg/mLwithPBSsolutioncontaining0.1%BSA.Murine
IFN-γ ELISAkitwaspurchasedfromPeproTech(RockyHill,
NJ) and used as recommended by the manufacturer. CRP
was measured in plasma using a mouse CRP ELISA kit (Life
Diagnostics, Inc., USA).
3.2. Immunoblotting of COX-2. Intestinal tissue samples
(ﬂushed with cold PBS) were ﬂash frozen in liquid nitrogen
before storing at −85
◦C. Frozen samples were weighed, and
3mLofRIP Abuﬀer (Santa Cruz Biotech, CA) (with PMSF
in DMSO, protease inhibitor cocktail, and sodium ortho-
vanadate) was added per gram of tissue. The samples were
homogenized, pooled, sonicated, and centrifuged at 4◦Cf o r
10 minutes at 10,000×g. The protein content was deter-
minedusingQuant-iTproteinassaykit(Invitrogen,Burling-
ton, Canada) with bovine serum albumin (BSA) as the
standard. Twenty micrograms of total proteins, as evaluated
by Quant-iT protein assay, from tissue were used for Western4 International Journal of Inﬂammation
blot. Aliquots containing protein were fractionated on 4–
12% Bis-Tris Gel (Invitrogen, Carlsbad, CA) at 120V for 2
hours. After electrophoresis, proteins were transferred from
the gel to a nitrocellulose membrane (Whatman, Maidstone,
Kent, UK) using Novex Semi-Dry Blotter (Invitrogen, Carls-
bad, CA). COX-2 mouse monoclonal antibody (1:1,000;
Santa Cruz Biotechnology, Santa Cruz, CA) was used as the
primary antibody. Horseradish peroxidase-conjugated goat
antimouse IgG was used as the secondary antibody (1:1,000;
Santa Cruz Biotechnology, Santa Cruz, CA). The membrane
was then developed with chemiluminescent agents (ECL,
BM Chemiluminescence Blotting Substrate (POD), Roche
Diagnostics, IN) and visualized in a Versa Doc Imaging
SystemusingsoftwareQuantityOne-4.5.1(Model5000,Bio-
Rad Laboratories (UK)). Western blot images were analyzed
using Image J software (http://rsb.info.nih.gov/ij/ (accessed
in December 2005, NIH, USA)).
3.3. Adenoma Classiﬁcation and Enumeration. The number
of adenoma, low-grade dysplasia, high-grade dysplasia, and
gastrointestinal intraepithelial neoplasias (GIN) was scored
by a blinded veterinary pathologist to the treatment in the
small and large intestine. The standards for the histological
assessment were established from the MMHCC-sponsored
symposium and are detailed on the MMHC web site
(http://emice.nci.nih.gov/emice/mouse models/organ mod-
els/gastro models/murine intestinal neoplasia/models color
ectal cancer).
3.4. Statistical Analyses. All results in this paper are means
calculated using Excel and expressed as means ± SEM or SD.
Student t-test was used to assess the statistical signiﬁcance
of the diﬀerences between test and control groups. Data was
considered signiﬁcant at P<. 05.
4. Results
Artiﬁcial cell microcapsules containing L. acidophilus were
prepared using the multistep preparation methods described
and were stored at 4◦C for use in experiments. Sterile
conditions and procedures were strictly adhered during
the process of microencapsulation. Results show that the
bacterial cells were able to survive the encapsulation process
and grow normally when obtained supernatant was plated
after breaking of the microcapsule membrane. The micro-
capsules contained, on average, 1010 cfu/mL of bacteria.
Freshly prepared microcapsules were spherical and opaque
on account of bacterial density. Morphological studies by
microscopicanalysisrevealedthatthemeancapsulediameter
was 433 ± 67μm, and they exhibited high homogeneity.
Bacterial cells were able to survive during the encapsulation
process and grow normally (data not shown).
4.1. Food Intake and Body Weights. Results show (Figure 1)
that all animals gained weight steadily up to week 16 of age
in control group (25 ± 1.1g) and in treatment group (25 ±
1.2g). All the animals maintained constant weight until 17
weeks of age after which the weight in control group animals
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Figure 1: The eﬀect of daily gavage of microencapsulated L.
acidophilus cells in 2% M.F. yogurt in ApcMin mice on animal body
weights and food intake (weekly food intake averaged per cage (4
animals)). Data represent the mean ± SEM per group; n = 24.
decreasedto20±1.2gwhereastreatmentgroupanimalscon-
tinued to increase in their weight up to 27 ±1.2g at the time
of sacriﬁce. The food consumption was consistent with body
weight gain and loss. Every week after week 14 of age, mice
in control group had a lower consumption than treatment
group animals. The potential weight gain from the caloric
intake originated from yogurt fat was not taken into account
due to its insigniﬁcant value of (0.125kcal) per gavage.
4.2. Serum IL-12. During the 17-week experimental period
animalserumwasusedtomeasurethelevelsofinﬂammatory
interleukin 12. Results show the concentration levels were
signiﬁcantly higher (weeks 5, 13, and 17, P<. 05) in
treatment animal group compared to control group animals
(Figure 2). At the time of sacriﬁce the average levels were
46.58 ± 16.96pg/mL and 158.58 ± 28.56pg/mL for control
and treatment animals, respectively.
4.3. Luminal IL-12. Concentrations of luminal IL-12 were
measured in 4 distinct parts of the small intestine: duo-
denum, jejunum, and proximal and distal ileum. In the
control group similar concentrations were found in all 4
intestinalsections(12.35±5.55pg/mL)(Figure 3(a)).Among
the treatment group, luminal IL-12 concentrations were
the lowest in the duodenum, 35.79 ± 16.13pg/mL, and
the highest in proximal ileum, 53.74 ± 14.29pg/mL. All
measurements were signiﬁcant when compared to control
(P<. 05).
4.4. Luminal IL-6. The concentration of luminal IL-6 was
measured in the same sections of the small intestine as IL-12.
Control group animals had statistically higher levels of IL-6
in all intestinal sections when compared to treatment group
animals (P<. 05). The IL-6 concentration was especially
highintheduodenumandjejunumofcontrolgroupanimalsInternational Journal of Inﬂammation 5
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Data represent the mean ± SD of concentration levels per group;
n = 24. Asterisks: statistical diﬀerences (P<. 05) when compared
to control.
115.07±27.12pg/mL and 116.29±38.92pg/mL, respectively
(Figure 3(b)).
4.5. Luminal TNF-α. The concentration of luminal TNF-
α was measured in the same manner as described for IL-6
and IL-12. Higher concentrations were detected in control
groupanimalsandwererelativelycomparableinallintestinal
sections (Figure 3(c)). The highest concentration was in
proximal ileum, 24.08 ±10.59pg/mL. The concentrations of
TNF-α in proximal ileum in treatment group animals were
statistically the lowest, 9.38 ±4.23pg/mL.
4.6. Luminal IFN-γ. There were signiﬁcantly higher concen-
trations of luminal IFN-γ in control group animals when
compared to those of the treatment group (Figure 3(d)). The
highest concentration of luminal IFN-γ was found in the
jejunum of the treatment group, 168.55 ± 11.55pg/mL. The
lowest concentration was found in the jejunum of control
group animals, 51.08 ±24.59pg/mL.
4.7. Luminal IL-1β. The diﬀerence in concentration of
luminal IL-1β was statistically signiﬁcant in jejunum, P<
.05 (Figure 4(a)). In control group animals it was found to
be 460.4 ± 68.45pg/mL whereas in the treatment group it
was found to be 180.09 ± 43.56pg/mL. In the duodenum,
proximal and distal ileum the concentration levels did not
diﬀer statistically from control.
4.8. Luminal Thromboxane B2. The thromboxane B2 con-
centration was especially high in all intestinal sections in
control animal group, and its range was from 51.27 ±
23.53pg/mL in duodenum to 35.50 ± 13.16pg/mL in distal
ileum (Figure 4(b)). On the contrary, the levels of throm-
boxane B2 found in treatment animal group were relatively
low, ranging from 3.31 ± 1.75pg/mL to 1.52 ± 0.62pg/mL.
Alltheconcentrationlevelsbetweengroupsineachintestinal
section were statistically signiﬁcant (P<. 05).
4.9. Luminal PGE2. The concentration of luminal PGE2 was
the highest in control animals in all intestinal sections, espe-
cially in duodenum 1836.55 ± 389.88pg/mL (Figure 4(c)).
The concentration of PGE2 correlated positively with the
totalnumberofadenomas,adenomaburden,andtherelative
proportion of medium-sized and large adenomas. PGE2
correlated negatively with the relative proportion of small
adenomas in treatment group. The lowest concentration of
PGE2 was found in treatment group in distal ileum 248.57±
126.88pg/mL.
4.10. C-Reactive Protein (CRP). C-reactive protein concen-
trations were measured using ELISA kit from plasma stored
at −85
◦C obtained from animals by cardiac puncture at the
time of sacriﬁce. The levels between control and treatment
group animals were not signiﬁcant (Figure 5). They were
foundtobe81.04±23.73ng/mLincontrolgroupand64.21±
16.64ng/mL in treatment group.
4.11. COX-2 Expression. Intestinal lysates obtained from
distal ileum were analyzed by Western blotting employing
antibodies speciﬁc for the COX-2 isoform. Figure 6 shows
representative Western Blot bands of the 72kD COX-2
protein. A higher expression level of COX-2 was found
in control group animals. Using Image J software, the
bands were analyzed and relative intensities for control and
treatment group animals measured. It was found that the
COX-2 in treatment group animals was 71% lower than that
in control group animals.
4.12. Adenoma Classiﬁcation and Enumeration. There were
on average 4.5 ± 1.46 tumors found per animal in control
group and 2.5 ± 1.60 tumors in treatment group. Most
found lesions were small GIN: a total of 66 in small intestine
of control group and 42 in large intestine of treatment-
receiving animals. In general, adenomas found in colon of
control group (4) and treatment group (2) animals were less
numerous. This is 44% decrease in total number of lesions
in treatment-receiving animals when compared to control
group animals.
5. Discussion
Cancer is a chronic pathologic process. Inﬂammation is
considered to be a particularly important factor in the
pathogenesis of the colorectal cancers. A period of time is
required for a cancer to develop, invade or metastasize, and
eventually kill the host. Diet and disease development are
strongly related in disease incidence. For instance, the so-
called “Western diet”, containing red meat, is considered to
betheleadingcauseofhighercolorectalcancerdevelopment.
The main objective of this study was to suppress the
occurrence of spontaneously developing polyps in animals
ensuring that the levels of inﬂammatory cytokines are as
low as possible. The immunoenhancing eﬀect of microen-
capsulated probiotic bacterial cells may be an important6 International Journal of Inﬂammation
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Figure 3: The eﬀect of treatment on luminal cytokine concentration levels found in duodenum, jejunum, and proximal and distal ileum:
I L - 1 2( a ) ,I L - 6( b ) ,T N F - α (c), and IFN-γ (d). Data represent the mean ± SD of concentration levels per group; n = 24. Asterisks: statistical
diﬀerences (P<. 05) when compared to control.
mechanism that reduces the growth of malignant tumors.
Thus the animals were administered with microencapsulated
probiotic bacterial cells daily. The assessment of animal
health was achieved by measuring the various inﬂammation
biomarkers at the time of sacriﬁce. Animals which received
daily treatment with probiotic yogurt formulation were able
not only to maintain their body weight but also to slightly
increase it, which is a general indication of an overall health.
They also had a higher food intake comparing to control
animals. This may further imply that the rate of disease
progression was slower.
Biomarkers are very beneﬁcial to identify pathological
processesbeforeindividualsbecomesymptomaticortoiden-
tify individuals who are susceptible to cancer [35]. Luminal
digesta obtained from the intestines were used to give an
indication of IL-1β, IL-6, IL-12, PGE2, Thromboxane B2,
TNF-α,I F N - γ, and CRP levels in the gastrointestinal tract
and CRP in the plasma at the time of sacriﬁce. Our results
showed an overall trend indicating notably lower inﬂamma-
tion in the small intestines in the animals receiving daily
treatment. As ApcMin mice develop spontaneous neoplasia
predominantly inthesmallintestine asopposed tothecolon,
this study investigated and validated the inﬂammatory state
of that organ. In the intestine, IL-1 has been shown to be an
importantinﬂammatorymediatorwhoselevelsareincreased
in inﬂammatory bowel disease [36, 37]. IL-1β is solely active
in its secreted form whereas IL-1α is mainly active in cell-
associated forms (intracellular precursor and membrane-
bound IL-1α). IL-1α is only rarely secreted in a limited
manner [38]. The assay showed higher concentrations of
IL-1β in all sections of the small intestine in control group
animals. In addition, IL-6 lower concentration and IL-12
higher levels were indicative of a slower progress of the
disease in treatment group animals. Similar results were
obtained for TNF-α and IFN-γ.
These ﬁndings are consistent with those from previous
studies [39], which further proves that inﬂammation plays
an important role in the development of cancer. Tumor
invasiveness can be assessed by measuring thromboxane
B2 and PGE2. Therefore, we compared the levels of
thromboxane B2 and PGE2 in the small intestines. PGE2
is one of the primary prostaglandins formed from theInternational Journal of Inﬂammation 7
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Figure 5: Comparison of plasma C-reactive protein (CRP) levels
between control and treatment mice measured by enzyme-linked
immunosorbent assay at the time of sacriﬁce; n = 24; error bars
represent SD. Asterisks: statistical diﬀerences (P<. 05) when
compared to control.
coupled metabolism of arachidonic acid by the COX-1 and
COX-2 and PGE synthases (microsomal and/or cytosolic).
Moreover, its activity inﬂuences inﬂammation, fertility and
parturition, gastric mucosal integrity, and immune modu-
lation [40, 41]. Accumulating evidence suggests that PGE2
has direct eﬀects in enhancing colonic epithelial cell survival
by stimulating cell proliferation and survival, tumor cells
invasiveness, and production of angiogenic agents [42].
HigherconcentrationsofPGE2 incontrolgroupanimalsfur-
ther show intestinal inﬂammation of a greater extent when
compared to treatment group animals. As it was postulated
before, the inducible cyclooxygenase isoenzyme, COX-2, is
signiﬁcantly overexpressed at sites of inﬂammation and in
various malignant tissues, with concomitant overproduction
of the major arachidonate metabolite, PGE2 [43].
Increased expression of CRPs has been described in
several diﬀerent malignancies, including colorectal [44],
gastric[45],lung[46],renal[47],andbreast[48]cancers.W e
have measured plasma concentrations of C-reactive protein
from animals at the time of sacriﬁce. Elevated levels of CRP
were detected in control group animals when compared8 International Journal of Inﬂammation
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Figure 6: Western blot showing COX-2 expression found in homogenized distal ileum of small intestine tissues in control and treatment,
animals, MW of COX-2-72kD. Samples were pooled per treatment and the average expression was obtained for the total of 24 per group.
The relative band intensities were calculated with Image J software (P = .018).
to animals receiving treatment. C-reactive protein remains
signiﬁcantly associated with a higher risk of colon cancer in
ApcMin mice. Nonetheless, CRP is a nonspeciﬁc marker of
inﬂammation, and additional studies of speciﬁc cytokines or
factors that regulate acute-phase response are necessary to
elucidate the mechanisms by which inﬂammation increases
the risk of colon cancer.
COX-2expressionhasalargeimpactonadenomagrowth
in ApcMin mice, where treatment with a COX-2-speciﬁc
inhibitor is known to markedly reduce both the numbers
andgrowthofadenomas[49].MarkedupregulationofCOX-
2 occurs in various cells including endothelial cells during
stress and in inﬂammatory conditions such as sepsis. As
COX-2 expression is induced by a number of cytokines
including TNF-α and IL-1, mitogens or growth factors,
lipopolysaccharide (LPS), and other inﬂammatory stimuli,
it was of crucial importance to verify its expression levels.
C O X - 2l e v e l sw e r ed i ﬀerent between control and treatment
groups, (we obtained 71% reduction of averaged inﬂam-
mation level in treatment-receiving animals) as expected,
further providing evidence that the animals in treatment
group have lower intestinal inﬂammation when compared to
control group animals.
As gastrointestinal intraepithelial neoplasias (GINs) are
theprecursorsofadenomasandlaterofintestinalcarcinoma,
it was interesting to note the highest polyp counts of these
lesions. Although ApcMin mice provide a genetically valid
model for studying and understanding intestinal tumorige-
nesis, its major drawback is that it diﬀers from the cancer
development in humans. For instance, in human, carcino-
genesis is a complex multistep, often including metastasis
process. The polyps found in ApcMin mice do not undergo
the process of metastasis [50]. Furthermore, adenomas in
ApcMin mice occur primarily in the small intestine whereas
tumors in human are generally restricted to the colon and
rectum. To improve the eﬀectiveness of polyp enumeration
and classiﬁcation, one needs to design an automated system
(protocol) that would allow consistency by implementing
universal guidelines and standards.
Several factors should be considered in the interpretation
of our ﬁndings. A major strength of the current study is that
it is a prospective study, and, thus, we can more conﬁdently
infer a temporal association between inﬂammation and the
occurrence of colon cancer. Compared to other studies
[51–53], we obtained greater reduction of inﬂammation
in ApcMin mice due to oral treatment with formulation
of microencapsulated probiotic bacterial cells and yogurt.
Based on the results of the present study, it is not possible
however, to explain the tumorigenesis in the ApcMin mouse
model by immunological responses. Although conﬁrmation
oftheseresultsisclearlywarranted,thisﬁnding,iftrue,could
have implications for prevention strategies. Additional stud-
ies are needed to clarify the mechanism of bacterial activity
and its impact on immunomodulating gastrointestinal tract.
6. Conclusions
In conclusion, daily oral administration of the microencap-
sulated probiotic formulation results in an overall decrease
in total number of intestinal lesions and general functioning
which leads to increasing host protection against various
pathologies. This study supports the role for supplemental
probiotics as a strategy both for suppressing inﬂammation
and for preventing colon cancer.
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